Stock A950130 ACCESS BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Access Bio, Inc.

Equities

A950130

KR8840090003

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 27/06/2024 am IST 		5-day change 1st Jan Change
6,680 KRW +1.37% Intraday chart for Access Bio, Inc. -1.18% -25.53%
2023 Access Bio, Inc. acquired an unknown minority stake in CuraPatient Inc. CI
2023 Tranche Update on Access Bio, Inc.'s Equity Buyback Plan announced on March 24, 2022. CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Access Bio, Inc. acquired an unknown minority stake in CuraPatient Inc.
CI
Tranche Update on Access Bio, Inc.'s Equity Buyback Plan announced on March 24, 2022.
CI
Tranche Update on Access Bio, Inc.'s Equity Buyback Plan announced on March 24, 2022.
CI
Tranche Update on Access Bio, Inc.'s Equity Buyback Plan announced on March 24, 2022.
CI
Tranche Update on Access Bio, Inc.'s Equity Buyback Plan announced on March 24, 2022.
CI
Access Bio, Inc. agreed to acquire Belight Investment for approximately KRW 130 billion.
CI
Access Bio, Inc's Equity Buyback announced on March 24, 2022, has expired with 1,840,483 shares, representing 5.22% for KRW 29,899.64 million.
CI
Access Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Access Bio, Inc.'s Equity Buyback Plan Extended till May 23, 2023.
CI
AirBoss Defense Group and Maddox Defense Partner With Access Bio to Deliver US-Made COVID Test Kits to Defense Logistics Agency; BOS Up 2.6%
MT
AirBoss Defense Group and Maddox Defense Partner With Access Bio to Deliver US-Made COVID Test Kits to Defense Logistics Agency
MT
AirBoss of America Brief: Defense Logistics Agency has awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract valued at up to US$410 Million to Access Bio
MT
AirBoss of America Brief: AirBoss Defense Group and Maddox Defense Partner With Access Bio to Deliver US-Made COVID Test Kits to Defense Logistics Agency
MT
Tranche Update on Access Bio, Inc.'s Equity Buyback Plan announced on March 24, 2022.
CI
Access Bio, Inc. announces an Equity Buyback for KRW 30,000 million worth of its shares.
CI
Access Bio, Inc. authorizes a Buyback Plan.
CI
Atomo Diagnostics Limited and Access Bio, Inc. Renegotiate Supply Agreements
CI
Vivera Pharmaceuticals Partners with Areum Bio LLC and Access Bio, Inc. to Expand the National Distribution of Emergency Use Authorized COVID-19 Rapid Tests
CI
Atomo Diagnostics Limited Receives FDA Clearance for Covid-19 Antibody Test
CI
Intrivo Diagnostics Secures National Distribution Agreement with McKesson Medical-Surgical for Access Bio CareStart™ COVID-19 Tests
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A950130 Stock
  4. News Access Bio, Inc.
  5. Highlights